Biologics CDMO Selection: Timeline Risks To Watch

By Ralf Otto, COO

Selecting a biologics contract development and manufacturing organization requires balancing aggressive clinical timelines with rigorous risk management. Navigating partner evaluation—from initial request for proposal through facility audits and tech transfer—presents critical decision points where oversights can cause severe project delays or costly rework. Key technical vulnerabilities often stem from misaligned quality management systems, inadequate analytical comparability, and unproven facility scalability. Establishing clear evaluation criteria around technical track records, transparent communication, and adaptable infrastructure helps prevent bottlenecks during scale-up. By identifying operational red flags early, biopharma leaders can structure realistic evaluation schedules and secure reliable partners aligned with long-term commercial goals.

Examine the strategic roadmap and risk factors by reading the full article.